Part D Redesign: MedPAC Finalizes Recommendations To Congress But COVID-19 Will Get In The Way

 
• By Cathy Kelly
Pills
MedPAC Aims To Tamp Down Specialty Drug Costs In Part D

More from Market Access

More from Pink Sheet